Dudediligence.

Tevogen Inc

TVGNNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

4.26M

on 2026-06-30, from 3.29M on 2024-03-31 10-Q ↗

Earlier counts are adjusted for the 1-for-50 reverse split; each bar's tip shows the count as filed.

1M2M3M4M1:50 splitMar2024JunSepDecMar2025JunSepDecMar2026Jun

Newest

$150.0M

S-3 of 2025-06-20. 2 prospectus supplements filed under it since. S-3 ↗

$50.0M

A.G.P./Alliance Global Partners, agreement of 2025-07-03. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

348K

Warrants of every class as tagged in the XBRL facts on 2026-06-30. 10-Q ↗

Cash

0.4 quarters

$1.1M on 2026-06-30 ÷ $2.9M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 11 of its filings are not read yet.

Also on file: a 1-for-50 reverse split, 2026-03-06 8-K ↗